Detrás de los titulares sobre el cáncer

Estudio: La prueba de detección de cáncer de próstata puede beneficiar a las personas con síndrome de Lynch

Initial results from the IMPACT trial show that PSA testing to screen for prostate cancer in people with Lynch syndrome can detect aggressive early prostate cancers. These findings support the use of PSA screening in men with Lynch syndrome, particularly men with an inherited mutation in an MSH2 or MSH6 gene. (Posted 11/10/22)

Este artículo está disponible en español.

Estudio: Los adolescentes y los adultos jóvenes responden bien al aprendizaje sobre el riesgo de cáncer familiar

Little is known about how awareness of hereditary cancer in a high-risk family affects the quality of life of teens and young adults. This study looked at the lifestyle choices, cancer awareness and quality of life of adolescents and young adults whose mothers had undergone testing for a BRCA mutation. (Posted 10/11/2022) Este artículo está disponible en español.

Estudio: El tratamiento con inhibidores de PARP para el cáncer de próstata metastásico muestra mayores beneficios en los hombres con mutaciones heredadas del BRCA

This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors.  (posted 9/6/2022)

Este artículo está disponible en español.

Estudio: Realizar actividad física puede disminuir los niveles de fatiga relacionados con el tratamiento contra el cáncer

Many cancer survivors experience fatigue during and after they complete treatment. This study looked at the effect of home-based physical activity on fatigue in cancer survivors. It also looked at whether frequent counseling encouraged people to start and continue their exercise routines.  (Posted 8/1/22). Este artículo está disponible en español.

Estudio: La carga financiera oculta de tratar los síntomas del cuidado del cáncer

Drugs commonly used to treat symptoms of cancer and cancer treatment side effects can cost thousands of dollars out of pocket for patients, depending on what drugs are used. (Posted 6/29/2022). Este artículo está disponible en español.

Estudio: ¿El consumo de edulcorantes artificiales aumenta el riesgo de padecer cáncer?

A large study of adults in France suggests that artificial sweeteners may increase the risk of certain cancers. (posted 6/21/2022). Este artículo está disponible en español.

Estudio: Relación del aumento de casos de cáncer de próstata metastásico con la disminución de las pruebas de detección

The number of people diagnosed with metastatic prostate cancer increased following a change in recommendations around the use of routine prostate cancer screening. (posted 6/13/22)

Este artículo está disponible en español.

Actualización: Nuevo fármaco aprobado para el cáncer de próstata metastásico

The FDA approved a new treatment for metastatic castration-resistant prostate cancer. They also approved a test that can be used to identify patients who would benefit from this new treatment.  (Posted 5/10/22)

Este artículo está disponible en español.

Estudio: El aumento en el uso de melatonina despierta preocupaciones

Adult use of melatonin as a sleep aid has increased even though its benefits and risks are not well understood. This study looked at trends in melatonin use over the last 19 years. (Posted 4/14/2022)

Este artículo está disponible en español.

Estudio: Medicamentos para fortalecer los huesos: disminución del riesgo de fracturas causadas por los tratamientos contra el cáncer de próstata metastásico

Skeletal problems, especially bone fractures, are common in patients with advanced prostate cancer. To prevent these, many guidelines recommend the use of bone-protecting agents during treatment. The importance of giving a bone-protecting agent when treating patients with metastatic castration-resistant prostate cancer and bone metastases was confirmed in early results of an ongoing phase III trial. (11/5/21)

Este artículo está disponible en español.